Table 2. . The number of eligibility criteria, the number of eligible patients and the hazard ratio of the progression-free survival of the original clinical trials and emulated RRMM trials with eligibility criteria under three scenarios using Flatiron Health database: the original criteria used in the trial, fully relaxed criteria and robust data-driven criteria (i.e., bootstrap AI pathfinder).

Trial name	Clinical trial			Original trial computable EC			Fully relaxed EC		Robust data-driven computable EC
	EC (n)	Pat. (n)	HR	EC (n)	Pat. (n)	HR	Pat. (n)	HR	EC (n)	Pat. (n)	HR
CASTOR	34	498	0.39 (0.28–0.53)	18	203	1.08 (0.69–1.71)	442	1.12 (0.82–1.52)	16	237	1.06 (0.70–1.62)
ASPIRE	40	792	0.69 (0.57–0.83)	16	325	0.60 (0.26–1.39)	982	1.26 (0.98–1.62)	16	325	0.60 (0.26–1.39)
ENDEAVOR	42	929	0.79 (0.65–0.96)	16	290	1.19 (0.84–1.69)	803	1.39 (1.12–1.72)	15	303	1.17 (0.82–1.65)
ELOQUENT2	42	646	0.70 (0.57–0.85)	18	317	1.59 (0.96–2.66)	713	1.79 (1.25–2.56)	15	378	1.38 (0.86–2.23)
POLLUX	26	569	0.37 (0.27–0.52)	18	315	0.68 (0.46–1.01)	676	0.83 (0.62–1.11)	17	335	0.62 (0.42–0.93)
NIMBUS	35	455	0.48 (0.39–0.60)	15	113	1.22 (0.63–2.37)	456	1.06 (0.79–1.44)	11	282	0.91 (0.62–1.36)
APOLLO	40	304	0.63 (0.47–0.85)	20	141	0.64 (0.39–1.05)	554	0.70 (0.54–0.90)	17	228	0.47 (0.32–0.70)
CANDOR	58	466	0.63 (0.46–0.85)	18	107	0.94 (0.37–2.38)	358	0.98 (0.66–1.45)	15	135	0.68 (0.28–1.66)
TOURMALINE	27	722	0.74 (0.59–0.94)	14	340	1.15 (0.80–1.67)	695	1.57 (1.18–2.08)	13	354	1.11 (0.78–1.59)

The fully relaxed criteria correspond to evaluating the hazard ratio of PFS of all the patients in the Flatiron Health database who took the treatments in the relevant line of therapy.

EC: Eligibility criteria; HR: Hazard ratio; Pat.: Patient; RRMM: Relapsed and refractory multiple myeloma.